StockNow
Calendar
Log in
Global Markets

Novo (NOVOB DC) says SELECT SWITCH CV data showed semaglutide reduced MACE risk by 6% vs tirzepatide in patients with type 2 diabetes

StockNow breaking-news AI analysis

Novo Nordisk reported SELECT SWITCH data showing semaglutide lowered MACE risk by 6% compared with tirzepatide in type 2 diabetes patients.

2 stocks
NVONovo-Nordisk A/S$38.41Current priceLLYEli Lilly & Co.$1,185.44Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Geopolitics

UKMTO notes of a report in the evening of September 28th; says a vessel was struck by an unknown projectile in the Strait of Hormuz; vessel is underway after a resulting fire was extinguished, with the crew safe.

FX/Bonds

[MARKET UPDATE] Strength in DXY weighing on EUR and GBP; a move which comes amidst a pick-up in global fixed benchmarks

Geopolitics

Iranian Parliament Speaker Ghalibaf says if Iran cannot sell oil, no one in the region will sell oil, and warns that if Iran’s security is not ensured, no infrastructure will be safe, ISNA reports